3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Head & Neck
2
Genitourinary
2
Endocrine
2
CNS
2
Thoracic
1
NET
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
4
Pancreatic Neoplasms
3
Sarcoma
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Cancer, Papillary
1
Thrombocytosis
1
Salivary Gland Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Interventions
Docetaxel
4
Cetuximab
4
pembrolizumab
3
Trastuzumab
3
Magnetic Resonance Spectroscopy
3
Fluorodeoxyglucose F18
3
Erlotinib Hydrochloride
3
Biopsy
3
trastuzumab deruxtecan
2
sargramostim
2
Taxes
2
SS1(dsFv)PE38
2
Radiotherapy
2
Polymerase Chain Reaction
2
Immunohistochemistry
2
Gene Expression Profiling
2
Carboplatin
2
Capecitabine
2
zanidatamab
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
tanespimycin
1
spartalizumab
1
pertuzumab
1
oncogene protein E7, Human papillomavirus type 16
1
neratinib
1
mercaptoundecahydrododecaborate
1
larotrectinib
1
fluoromisonidazole
1
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
entrectinib
×
Gastrointestinal
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA